Specific treatment of ATTR-CM in Germany—expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK) - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Guidelines for the Management of ATTR-CM in Germany: Consensus from the German Society of Amyloid Diseases and the German Cardiac Society

  • By

  • Fabian aus dem Siepen

  • Teresa Trenkwalder

  • Birgit Aßmus

  • Ingrid Kindermann

  • Daniel Lavall

  • Sebastian Spethmann

  • Lars Michel

  • Timon Hansen

  • Sebastian Kruck

  • Christoph Rischpler

  • Fabian Knebel

  • Stéphanie K. Schwarting

  • Udo Bavendiek

  • Maria Papathanasiou

  • Ute Hegenbart

  • Ali Yilmaz

  • Katrin Hahn

  • Alexander Carpinteiro

  • Roman Pfister

  • Caroline Morbach

  • September 22, 2026

Share

  • 1

    ATTR-CM is increasingly recognized as a cause of heart failure, with two classes of approved treatments in Germany: TTR stabilizers and TTR gene silencers.

  • 2

    Tafamidis and acoramidis are the two approved TTR stabilizers in Germany, while vutrisiran is a TTR gene silencer that is expected to be approved for treatment in 2025.

  • 3

    Tafamidis has demonstrated efficacy in clinical trials, significantly reducing all-cause mortality and cardiovascular hospitalizations compared to placebo.

  • 4

    Long-term follow-up indicates that tafamidis has a favorable safety profile, with adverse events primarily being mild or moderate and similar to those observed with placebo.

  • 5

    Tafamidis may provide benefits in stabilizing neuropathy progression in ATTRv patients, particularly when treatment is initiated early.

Original Source(s)

Specific treatment of ATTR-CM in Germany—expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK)

  • by Fabian aus dem Siepen, Teresa Trenkwalder, Birgit Aßmus, Ingrid Kindermann, Daniel Lavall, Sebastian Spethmann, Lars Michel, Timon Hansen, Sebastian Kruck, Christoph Rischpler, Fabian Knebel, Stéphanie K. Schwarting, Udo Bavendiek, Maria Papathanasiou, Ute Hegenbart, Ali Yilmaz, Katrin Hahn, Alexander Carpinteiro, Roman Pfister, Caroline Morbach

  • September 22, 2026

Related Content

FDA guidance spurs adoption of change control plans for radiology AI devices

Investigators examined adoption and public documentation of change control plans for FDA-cleared radiology AI devices.

Predictive value of the serum sodium to log(D-dimer) ratio for the risk of all-cause death in patients with chronic heart failure with different ejection fractions

Tricuspid regurgitation thresholds reassessed

The proposed framework classified 30% of patients as high or extreme risk, compared with 12% classified as having severe or greater tricuspid regurgitation under established grading schemes.